新華都(002264.SZ):2015年員工持股計劃減持完畢暨計劃終止
格隆匯 3 月 2日丨新華都(002264.SZ)公佈,公司2015年員工持股計劃所持公司股票已通過集中競價交易方式全部減持完畢。
2019年6月17日至2021年3月1日期間,此次員工持股計劃通過集中競價交易方式累計減持公司股票104.6萬股,佔公司最新總股本約6.85億股的0.15%。截至公吿日,此次員工持股計劃所持公司股票已全部減持完畢,此次員工持股計劃實施期間,公司嚴格遵守股票市場交易規則及中國證券監督管理委員會、深圳證券交易所關於信息敏感期不得買賣股票的規定,未利用任何內幕信息進行交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.